for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sangamo Therapeutics Inc

SGMO.O

Latest Trade

5.76USD

Change

-0.18(-2.95%)

Volume

1,432,611

Today's Range

5.71

 - 

6.04

52 Week Range

5.71

 - 

15.70

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.93
Open
5.88
Volume
1,432,611
3M AVG Volume
31.55
Today's High
6.04
Today's Low
5.71
52 Week High
15.70
52 Week Low
5.71
Shares Out (MIL)
145.67
Market Cap (MIL)
876.96
Forward P/E
-4.55
Dividend (Yield %)
--

Next Event

Q4 2021 Sangamo Therapeutics Inc Earnings Release

Latest Developments

More

Sangamo Therapeutics Reports Recent Business And Clinical Highlights And Q3 2021 Financial Results

Sangamo Therapeutics QTRLY Loss Per Share $0.33

Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, To CFO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company is focused on translating science into medicines that transform the lives of patients with serious diseases. Its product candidates include Giroctocogene fitelparvovec (SB-525), ST-920, SAR445136, ST-400 and TX200. Its SB-525, is a lead product candidate, a gene therapy for the treatment of hemophilia A. Its ST-920, is a gene therapy product candidate for the treatment of fabry disease. SAR445136, is its cell therapy product candidate for the treatment of sickle cell disease (SCD). Its ST-400 is a cell therapy product candidate for the treatment of transfusion dependent beta thalassemia. Its TX200, is a chimeric antigen receptor (CAR), engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection.

Industry

Biotechnology & Drugs

Contact Info

7000 MARINA BLVD

BRISBANE, CA

94005

United States

+1.510.9706000

https://www.sangamo.com/

Executive Leadership

H. Stewart Parker

Independent Chairman of the Board

Alexander D. Macrae

President, Chief Executive Officer, Director

Prathyusha Duraibabu

Chief Financial Officer, Senior Vice President

D. Mark McClung

Executive Vice President, Chief Business Officer

R. Andrew Ramelmeier

Executive Vice President - Technical Operations

Key Stats

2.09 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.1K

2021(E)

0.1K
EPS (USD)

2018

-0.700

2019

-0.850

2020

-0.900

2021(E)

-1.324
Price To Earnings (TTM)
--
Price To Sales (TTM)
8.08
Price To Book (MRQ)
2.16
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-24.50
Return on Equity (TTM)
-20.91

Latest News

Latest News

Pfizer's hemophilia gene therapy shows sustained effect in early-stage study

Pfizer Inc and Sangamo Therapeutics Inc said on Thursday their gene therapy helped maintain levels of a vital protein for up to 14 months in patients with a rare genetic disorder in which blood does not clot easily.

BRIEF-Sangamo Therapeutics Reports Q4 EPS Of $0.04

* SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Sangamo Therapeutics Increased Size Of Board To Nine Members From Eight

* SANGAMO THERAPEUTICS INC - ON FEB 11, BOARD OF DIRECTORS INCREASED SIZE OF BOARD TO NINE MEMBERS FROM EIGHT Source: (https://bit.ly/3266fYZ) Further company coverage:

BRIEF-Sangamo Therapeutics Appoints John Markels To Board Of Directors

* SANGAMO THERAPEUTICS APPOINTS JOHN MARKELS TO ITS BOARD OF DIRECTORS

Sangamo Therapeutics shares dive after poor early-stage trial data

Sangamo Therapeutics Inc's shares sank 27 percent on Thursday after its gene-editing drug failed to show promise in an early-stage trial testing it in patients with ultra-rare disorders.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up